BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Sold by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. cut its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 26.9% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 386,885 shares of the biotechnology company's stock after selling 142,534 shares during the quarter. Assenagon Asset Management S.A. owned about 0.19% of BioCryst Pharmaceuticals worth $1,965,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Los Angeles Capital Management LLC grew its stake in shares of BioCryst Pharmaceuticals by 68.0% during the 1st quarter. Los Angeles Capital Management LLC now owns 89,614 shares of the biotechnology company's stock worth $455,000 after purchasing an additional 36,284 shares during the period. Vanguard Group Inc. grew its stake in shares of BioCryst Pharmaceuticals by 15.4% during the 4th quarter. Vanguard Group Inc. now owns 17,763,720 shares of the biotechnology company's stock worth $106,405,000 after purchasing an additional 2,371,401 shares during the period. Counterweight Ventures LLC acquired a new position in shares of BioCryst Pharmaceuticals during the 4th quarter worth $81,000. Quarry LP acquired a new position in shares of BioCryst Pharmaceuticals during the 4th quarter worth $54,000. Finally, Braidwell LP grew its stake in shares of BioCryst Pharmaceuticals by 6.6% during the 4th quarter. Braidwell LP now owns 5,718,477 shares of the biotechnology company's stock worth $34,254,000 after purchasing an additional 355,497 shares during the period. 85.88% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the stock. Needham & Company LLC reissued a "buy" rating and issued a $12.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday, May 7th. HC Wainwright reissued a "buy" rating and issued a $30.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday, May 7th. Finally, JMP Securities increased their price objective on shares of BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the company a "market outperform" rating in a research note on Tuesday, May 7th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $14.00.

Insider Buying and Selling at BioCryst Pharmaceuticals

In related news, insider Helen M. Thackray acquired 30,000 shares of the business's stock in a transaction dated Tuesday, May 14th. The shares were acquired at an average cost of $5.86 per share, for a total transaction of $175,800.00. Following the acquisition, the insider now directly owns 272,139 shares in the company, valued at approximately $1,594,734.54. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, CFO Anthony Doyle acquired 36,300 shares of the business's stock in a transaction dated Tuesday, May 14th. The shares were acquired at an average cost of $5.57 per share, for a total transaction of $202,191.00. Following the acquisition, the chief financial officer now directly owns 266,744 shares in the company, valued at approximately $1,485,764.08. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Helen M. Thackray acquired 30,000 shares of the business's stock in a transaction dated Tuesday, May 14th. The shares were bought at an average price of $5.86 per share, for a total transaction of $175,800.00. Following the completion of the acquisition, the insider now owns 272,139 shares in the company, valued at $1,594,734.54. The disclosure for this purchase can be found here. In the last ninety days, insiders have bought 88,240 shares of company stock worth $498,442. Corporate insiders own 4.40% of the company's stock.

BioCryst Pharmaceuticals Price Performance

NASDAQ:BCRX traded down $0.15 on Monday, reaching $6.13. The stock had a trading volume of 3,620,954 shares, compared to its average volume of 3,495,856. The company has a market cap of $1.27 billion, a price-to-earnings ratio of -5.73 and a beta of 1.96. The firm's fifty day moving average is $4.96 and its two-hundred day moving average is $5.47. BioCryst Pharmaceuticals, Inc. has a 12-month low of $4.03 and a 12-month high of $8.96.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last released its earnings results on Monday, May 6th. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.23) by $0.06. The firm had revenue of $92.80 million during the quarter, compared to analysts' expectations of $85.62 million. BioCryst Pharmaceuticals's revenue for the quarter was up 34.9% on a year-over-year basis. During the same quarter last year, the company posted ($0.28) earnings per share. As a group, research analysts forecast that BioCryst Pharmaceuticals, Inc. will post -0.66 earnings per share for the current fiscal year.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.